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Introduction and historical background
Evolving concepts of disease mechanisms for rheumatoid
arthritis (RA) have provided a paradigm for understanding
the pathogenesis of autoimmune disease. This paradigm
proposes that genetic and environmental factors shape a
complex series of molecular and cellular interactions
leading to a chronic inflammatory response. CD4+ T lym-
phocytes have featured prominently because the genetic
elements most strongly associated with RA susceptibility
or severity are encoded within the MHC class II region
(discussed in this issue in the chapters by H McDevitt,
and G Sønderstrup). Precisely how effector T cells initiate
and promote the inflammatory process in RA, however,
remains far from clear. Much effort has focussed on estab-
lishing the molecular nature of antigenic reactivity, in the
belief that the established chronic phase of the disease is
antigen-driven. Animal models of inflammatory arthritis
would certainly lend support to this view. However, the
results of detailed phenotypic and functional analyses of
chronically activated T cells derived from inflamed joints
are difficult to reconcile with traditional models of carti-
lage-antigen-driven inflammatory disease in patients with
RA. This chapter aims to explore this theme in more depth,
beginning with an outline of the molecular events that
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Chapter summary
The strong association between specific alleles encoded within the MHC class II region and the
development of rheumatoid arthritis (RA) has provided the best evidence to date that CD4+ T cells play
a role in the pathogenesis of this chronic inflammatory disease. However, the unusual phenotype of
synovial T cells, including their profound proliferative hyporesponsiveness to TCR ligation, has
challenged the notion that T-cell effector responses are driven by cognate cartilage antigens in
inflamed synovial joints. The hierarchy of T-cell dysfunction from peripheral blood to inflamed joint
suggests that these defects are acquired through prolonged exposure to proinflammatory cytokines
such as tumour necrosis factor (TNF)-α. Indeed, there are now compelling data to suggest that chronic
cytokine activation may contribute substantially to the phenotype and effector function of synovial
T cells. Studies reveal that chronic exposure of T cells to TNF uncouples TCR signal transduction
pathways by impairing the assembly and stability of the TCR/CD3 complex at the cell surface. Despite
this membrane-proximal effect, TNF selectively uncouples downstream signalling pathways, as is
shown by the dramatic suppression of calcium signalling responses, while Ras/ERK activation is
spared. On the basis of these data, it is proposed that T-cell survival and effector responses are driven
by antigen-independent, cytokine-dependent mechanisms, and that therapeutic strategies that seek to
restore T-cell homeostasis rather than further depress T-cell function should be explored in the future.
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dictate the differentiation of T helper (Th) cells at the
outset of adaptive immune responses in regional lymph
nodes. Much of the remainder of the discussion focuses
on the different ways in which, in the longer term, the
chronic inflammatory process influences maturation, differ-
entiation, and function of effector T cells at sites of inflam-
mation. I conclude by speculating about how our
understanding of T-cell activation in chronic inflammation
may influence future therapy, and discuss this in the context
of the prevailing view that in a susceptible host, chronic
inflammatory disease occurs through a failure of regulatory
T cells to downregulate the inflammatory process.
Acquisition of transcriptional competence
during differentiation of T helper cells
There is now good evidence that there exists a coordi-
nated programme of molecular events initiated at the
outset of T-cell differentiation that leads to the generation
of CD4+ Th effector cells [1]. This process of differentia-
tion is characterised by a distinctive pattern of cytokine
production and is important because its outcome dictates
the host response to foreign pathogens such as Listeria
monocytogenes infection or to parasitic infestation [2]. For
cytokine genes, at least three stages are thought to be
required for the acquisition of transcriptional competence
in T cells: an initiation phase, a commitment phase, and a
phase of acute gene transcription (Fig. 1). The existence
of these stages has been deduced largely from experi-
ments in which monospecific T cells are stimulated in vitro
in bulk cultures from naïve precursors [3,4]. During the ini-
tiation phase, naïve T cells are engaged through their T-
cell receptors (TCRs) by MHC/peptide complexes
expressed on the surface of dendritic cells. Only those T
cells that form a functional immunological synapse are
likely to differentiate [5]. At this point, intracellular sig-
nalling pathways emanating from stable clusters of
TCR/CD3 complexes are integrated with those from
cytokine receptors following engagement by cytokines.
For example, IL-12 and IL-18 are important for differentia-
tion of Th1 cells but also play a key role in innate immunity.
In polarised Th cells, some cytokines activate families of
transcription factors called ‘signal transducers and activa-
tors of transcription’, or STATs, such as STAT4 for IL-12
(Th1), or STAT6 for IL-4 (Th2) [6]. The initial engagement
phase may last from hours to days, and in general will
result in the production of IL-2 and entry of the cell into the
cell cycle. At this stage, cells are incapable of producing
Th1 (IFN-γ) or Th2 (IL-4) cytokines, despite optimal stimu-
lation by antigenic peptide and cytokines. Moreover, sur-
prisingly few T cells progress beyond this early stage of
maturation.
The commitment phase is characterised at the molecular
level by the induction and recruitment of Th-subset-spe-
cific transcription factors. Those considered to be lineage-
specific include GATA-3 and c-Maf for Th2 cells [7,8], and
T-bet and ERM for Th1 cells [9,10]. Once these factors
are expressed, differentiation is stabilised and maintained
even in the absence of further TCR stimulation (see Fig. 1,
middle panel). The third phase, that of acute gene tran-
scription, is determined by secondary contact with antigen
and necessitates the recruitment of nuclear factor of acti-
vated T cells (NFAT) together with subset-specific tran-
scription factors to the transcriptosome complex (see
Fig. 1, right panel). This process is thought to be monoal-
lelic and stochastic, probably because it depends upon
chromatin accessibility [1,6]. Thus, specific loci become
transcriptionally active through a series of changes to
chromatin structure, including chromatin decondensation
and remodelling, and recruitment of complexes to the
nuclear matrix [11]. Within 48 hours of stimulation, new
clusters of DNase-hypersensitive sites can be detected,
as demonstrated for the IL-4 gene [12], possibly through
the coordinated action of STATS and other transcription
factors such as the binding of p300 and of calcium-
binding proteinC/EBP (CCAAT/enhancer binding protein)
to DNA elements [1,6]. These sites are markers of stable,
differentiated T cells. Coincident with these changes in
the nucleus are overall increases in histone acetylation,
histone phosphorylation, and DNA demethylation [13,14],
which occur during the S phase of the cell cycle [15].
Full commitment to a specific lineage is established gradu-
ally and in most cases takes place in regional lymph
nodes. According to this model, Th cells can be thought of
as being in ‘antigen mode’, since the transcriptional pro-
gramme required for effector function is absolutely deter-
mined by antigen and TCR signalling pathways. It follows
from this that the expression and stability of the TCR on
the T-cell surface, its avidity for MHC/peptide complexes,
the signal strength, and the integrity of protein tyrosine
kinases and signalling adaptor molecules would be essen-
tial in determining both qualitative and quantitative charac-
teristics of the immune response [16].
T-cell differentiation in chronic inflammation –
clues from the rheumatoid joint
While these molecular events go some way towards
explaining why some CD4+ T cells differentiate into Th1
cell subsets and produce IFN-γ while others are destined
to become Th2 cells producing IL-4, IL-5, and IL-13, much
less is known about the events that regulate T-cell effector
responses in the context of chronic immunoinflammatory
responses. Part of the problem lies in accessibility to T
cells at sites of inflammation available for study, the het-
erogeneity of T-cell subsets recruited to these sites, the
unpredictable immunomodulatory effects of drug therapy,
and the relapsing and remitting nature of the disease
process itself. Notwithstanding these issues, it has been
possible to draw some tentative conclusions based on the
phenotype of T cells isolated from inflamed tissue such as
the RA synovial joint.S199
What do the available data tell us about T-cell activation
and differentiation in established chronic inflammation?
The evidence for chronic immune activation is unambigu-
ous (Table 1). This is best illustrated by histological analy-
ses of sections of synovial tissue in which, in subsets of
patients with more severe RA, there exist perivascular fol-
licular lymphoid-like structures resembling germinal
centres of lymphoid organs [17,18]. Lymphoid aggregates
in synovial tissue are rich in T cells, B cells expressing
MHC class II, and dendritic cells, and their precise cellular
organisation is thought to depend on the local expression
of cytokines and chemokines [19]. Ex vivo, flow cytometric
analysis reveals a memory phenotype for synovial tissue
and fluid T cells expressing CD45RO but low levels of
CD45RB [20,21], suggestive of past or persistent anti-
genic stimulation. Their cell surface carries other markers
of activation, such as CD69, CD44, and HLA-DR, as well
as the chemokine receptors CCR4, CCR5, CXCR3, and
CX3CR1, whose selective expression may facilitate
homing to synovial joints [20,22]. Synovial T cells persist
in the joint, possibly through an environment that favours
cell survival. The expression of stromal cell derived survival
factors such as IFN-α may contribute [23]. The demon-
stration of both significant and premature telomere short-
ening would also suggest that these cells undergo
progressive self-replication in situ [24], and so by the time
the inflammatory process is established, subsets of syn-
ovial T cells may already be approaching the stage of ter-
minal differentiation or senescence.
While there is a general consensus that in inflamed syn-
ovial joints there is enrichment of Th1 T cells [25], the
demonstration of significant populations of polarised Th1
subsets has been difficult, even with the advent of intracel-
lular staining techniques [26,27]. Indeed, expression of
cytokines cannot be detected easily without stimulation,
and even after stimulation with anti-CD3 and anti-CD28,
the frequency of cytokine-expressing cells may be very
low, necessitating pharmacological stimulants (e.g.
phorbol ester and ionophore) to demonstrate the pres-
ence of cytokine-producing T cells. Nonetheless, the
finding of a paucity of Th2-cytokine-expressing T cells by
many laboratories has been more consistent [25,28], and
recently there are data to suggest that naïve RA peripheral
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Figure 1
Acquisition of transcriptional competence during differentiation of T helper cells. Th cells become productive effectors of immunoinflammatory
responses following a complex series of molecular events dependent upon membrane-proximal TCRs and cytokine receptor signals. Chromatin
remodelling is an essential step in the process leading to a switch from the ‘closed’ to ‘open’ DNA conformation. This in turn permits accessibility of
Th-subset-specific transcription factors and accessory factors to the promoter elements of the Th2 gene cluster, as illustrated here. Ultimately, NFAT
is recruited to the transcriptosome, after which cytokine gene transcription proceeds. c-Maf, transcription factor specific for Th2 cells; 
ERM, transcription factor specific for Th1 cells; GATA-3, transcription factor specific for Th2 cells; NFAT, nuclear factor of activated T cells; 
STAT, signal transducer and activator of transcription; T-bet, transcription factor specific for Th1 cells; TCR, T-cell receptor; Th, T helper (cell).S200
blood T cells may be refractory to Th2 differentiation [29].
According to these data, there exists in vivo an imbalance
between proinflammatory cytokines and anti-inflammatory
cytokines whereupon a deficiency of anti-inflammatory
cytokines might be expected to favour the failure of
immunoregulatory mechanisms [30]. Taken together,
these experimental observations go some way towards
supporting the idea that in inflamed synovial joints, the T
cell is in a state of chronic immune activation, if not to say
a state of chronic stress or exhaustion, and that the default
regulatory mechanisms operating in the nonsusceptible
host are absent or insufficient.
Synovial T cells are hyporesponsive to TCR
engagement
The low levels of constitutive cytokine expression in syn-
ovial T cells is puzzling, given their activated phenotype.
More puzzling is the finding that they proliferate very poorly
in vitro in response to either mitogen, recall antigens, or
CD3 ligation with specific agonistic monoclonal antibodies
(Table 1, and [31–33]). Indeed, suppression of proliferative
and cytokine responses has led some workers in the field
to conclude that terminally differentiated T cells may not
contribute to the established inflammatory response [34].
However, this does not seem compatible with the
histopathological features of inflamed joints outlined above.
There are several possible reasons for the unusual pheno-
type of synovial T cells, which may have to do with both
spatial and temporal parameters. Firstly, the anatomy and
cellular environment of inflamed synovial tissue are differ-
ent from the architecture and cellular constituents of
lymph nodes, with hypoxia and extremes of extracellular
pH imposing significant pathophysiological effects (dis-
cussed in this issue in chapters by P Taylor and E Pale-
olog). Secondly, extensive analysis of the inflammatory
environment demonstrates that the cytokine milieu in RA
synovial tissue is different from that expressed in a lymph
node during primary interactions between dendritic cells
and precursors of Th cells, with a strong predominance of
macrophage products [30]. Accordingly, the expression of
cytokine receptors and the acquisition of chronic cytokine
responsiveness is likely to be a distinguishing feature of
chronically activated T cells in inflamed joints. Historically,
it has been assumed that T-cell activation in the rheuma-
toid joint would be driven by peptide fragments of carti-
lage antigens presented by disease-associated
MHC-class-II molecules [35,36]. However, this model now
has to take into account the fact that synovial T cells are
hyporesponsive to TCR engagement. These findings raise
the possibility that during the evolution of immune and
inflammatory responses, the balance of stimulation shifts
from ‘antigen mode’, in which T cells are engaged through
the TCR/CD3 complex during the early phases of Th dif-
ferentiation, to ‘inflammation mode’, in which T-cell activa-
tion and effector responses are driven by proinflammatory
cytokines (Fig. 2).
A model of T-cell activation in chronic
inflammation
Almost a decade ago, we began to think about ways to
explore how the chronic inflammatory process might influ-
ence T-cell autoreactivity and effector responses, in the
belief that this might contribute to an understanding of the
immunopathogenic processes involved in the chronic
phase of RA. Our approach was influenced to a great
extent by a series of observations arising from a larger pro-
gramme of work in the laboratory and by others, which
sought to document in depth the broad range of cytokines
expressed in rheumatoid joints. The observations of partic-
ular importance included the findings that tumour necrosis
factor (TNF)-α bioactivity persists in synovial joint cell cul-
tures and in vivo [37–40]; that both high-affinity p55 and
p75 tumour-necrosis-factor receptors (TNFRs) are upreg-
ulated on synovial joint T cells [41]; that TNFRs are
expressed in lymphoid aggregates and colocalise with
ligand [42]; and that expression of the naturally occurring
TNF inhibitors, the soluble TNFRs, is also increased in
synovial fluid but is insufficient to completely neutralise
bioactive TNF in vivo [43]. The implication of these find-
ings was that synovial mononuclear-cell infiltrates, includ-
ing T cells, are chronically exposed to TNF in vivo. We
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Table 1
Characteristics of chronically activated T lymphocytes in the synovium of patients with rheumatoid arthritis
1 T lymphocytes are found in follicular lymphoid aggregates
2 The cell-surface phenotype is suggestive of chronic immune activation, e.g. expression of CD45RO, CD69, and subsets of chemokine receptors
3 T cells are terminally differentiated, with significant telomere loss
4 Synovial T cells are hyporesponsive to TCR ligation
5 Synovial T cells exist in an environment favouring cell survival
6 There is an imbalance of pro- and anti-inflammatory cytokines, with a predominance of macrophage products in inflamed joints
7 There is a bias towards the development of T helper (Th)1 cellsS201
therefore predicted that the environment generated in
chronically inflamed joints must be very different from that
provided by an acute inflammatory or infectious episode
(Table 1), and that chronic exposure to inflammatory
cytokines might have effects distinct from those induced
after short-term exposure.
We set out to mimic chronic exposure to cytokines by cul-
turing antigen-activated T cells in the presence of TNF.
This in vitro model was very similar to that used in many
laboratories to explore the effects of cytokines such as
IFN-γ, IL-4, and IL-12 on T-cell differentiation [3,4], with
the exception that recombinant TNF was added repeat-
edly to T-cell cultures to mimic better the sustained TNF
signalling we believed existed in inflamed joints (Fig. 3)
[44]. The principal finding that chronic, as opposed to
acute, exposure to TNF suppressed T-cell activation was
unambiguous, and could not have been predicted from
published data at that time, which suggested that TNF
was costimulatory and a growth factor for T cells [45].
These results have been confirmed in other laboratories
[46–48] and have been supported further through exten-
sive analyses of both human and murine T-cell lines and
clones in vitro, as well as from experiments in vivo under-
taken in T-cell receptor transgenic mice treated with
recombinant TNF, anti-TNF, or after intercrossing to
human-TNF-globin transgenic mice [49,50]. The findings
are summarised in Table 2. Two lines of evidence con-
vinced us that these unexpected findings were potentially
important and worthy of further investigation. The first was
the observation that peripheral blood T-cell responses
from patients with RA were dramatically and rapidly
restored after treatment with anti-TNF (infliximab, Remi-
cade™) [44] and that these immunological parameters
closely followed clinical improvement [51]. The second
line of evidence came from a series of studies undertaken
in TCR transgenic mice. These experiments revealed that
repeated injections of otherwise healthy transgenic mice
with anti-TNF enhanced T-cell responses to cognate
peptide antigen, and implied that physiological concentra-
tions of TNF had immunomodulatory properties in vivo
[49].
The immunomodulatory effects of TNF in the
initiation and resolution of autoimmunity
Until the late 1980s, it was assumed that TNF was both
proinflammatory and co-stimulatory [30]. How could these
initial observations be reconciled with the immunosuppres-
sive effects outlined above? An extensive series of studies
in mice deficient for TNF or TNFR have confirmed that TNF
has potent immunomodulatory effects in vivo, capable of
regulating T-cell autoreactivity and autoimmunity  when
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Figure 2
A model for the role of CD4+ T cells in the pathogenesis of chronic inflammation. Antigen drive predominates during the early phase of
inflammatory responses (‘antigen mode’). In a nonsusceptible host, the immune response resolves through mechanisms such as activation-induced
cell death and/or the production of immunoregulatory cytokines. In the susceptible host, additional T cells are recruited to sites of inflammation
through bystander activation, or by stimulation with self antigens released from inflamed tissues. As the inflammatory process progresses, chronic
cytokine production induces profound nondeletional T-cell hyporesponsiveness. Hyporesponsive T cells function as effector cells and sustain the
chronic inflammatory process through predominantly antigen independent mechanisms (‘inflammation mode’). It is proposed that by reversing T-cell
hyporesponsiveness, antigen-dependent responses that serve to regulate the inflammatory process (e.g. through expression of immunoregulatory
cytokines) are restored.S202
studied in autoimmune-susceptible strains of mice [50].
Indeed, the suppressive effects of chronic TNF were
entirely consistent with the studies of Jacob and McDevitt
[52], as well as Gordon and colleagues [53], who first
demonstrated the disease-protecting effects of chronic
TNF therapy in the NZB/W F1 lupus-prone mouse. Similar
effects were reported subsequently in murine models of
type I diabetes [54,55]. Using a mouse model of multiple
sclerosis, Kollias and colleagues demonstrated that while
acute TNF exposure is important for T-cell priming to
cognate antigen, chronic TNF is required for resolution of
T-cell reactivity to myelin antigens [56]. They found that
the initiation of T-cell reactivity to myelin basic protein or
myelin oligodendrocyte glycoprotein in TNF-deficient mice
of the H-2b strain, which is normally resistant to experi-
mental autoimmune encephalomyelitis, was dramatically
impaired, consistent with the idea that TNF was an
absolute pre-requisite for T-cell priming by antigen.
However, by following the T-cell responses to self-anti-
gens over time, it became apparent that while antigen
reactivity peaked and then declined to concentrations no
longer detectable in wild-type mice, responses gradually
increased and became sustained in TNF-deficient litter-
mates many weeks after immunisation. This sustained and
uncontrolled autoreactivity to myelin oligodendrocyte gly-
coprotein correlated closely with the development of a
chronic demyelinating disease in an otherwise disease-
resistant strain [56]. These data provide compelling evi-
dence to suggest that while short-term TNF is important
for antigen priming, sustained TNF expression is neces-
sary for resolution of T-cell responses (Fig. 4).
How does chronic TNF attenuate T-cell
activation?
The potent immunodulatory effects of prolonged TNF
exposure in vitro and in vivo in both mouse and man has
prompted us to explore in more depth the molecular and
biochemical basis for these findings, in the belief that an
understanding of the processes involved might unravel
one of nature’s immunosuppressive mechanisms. There-
fore, we began to study TNF effects on T-cell hybridomas,
since these cells could be propagated in the absence of
accessory cells. Using this model, we found that the sup-
pression of IL-2 production (to 10% of that in control
T cells) was the most profound that we had observed to
date. Our first series of experiments revealed that chronic
TNF stimulation increased the threshold for T-cell activa-
tion through the TCR, such that more peptide/MHC com-
plexes were required for longer periods of time for
TNF-treated T cells to commit to IL-2 production [57].
Closer scrutiny of TNF-treated T cells revealed both dose-
and time-dependent reductions in expression of the
TCR/CD3 complex at the cell surface, as determined by
flow cytometry or by cell surface immunoprecipitation
experiments. In contrast, levels of expression of CD3ε in
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Figure 3
Model for studying the effects of TNF on T-cell differentiation and maturation. T cells are stimulated with cognate antigen in the presence of
irradiated antigen-presenting cells for periods of up to 14 days in the presence or absence of recombinant TNF. Cytokines are added to cultures
every 2 or 3 days. At the end of the culture period, T cells are washed extensively and then rechallenged with specific antigen or anti-CD3 mAb in
the absence of TNF. APC, antigen-presenting cell; T, T cell; TNF, tumour necrosis factor-α.
Table 2
Characteristics of CD4+ T cells chronically exposed to tumour
necrosis factor
1 Upregulation of activation antigens such as CD69
2 Induction of nondeletional, proliferative hyporesponsiveness
3 Suppression of cytokine production
4 Uncoupling of TCR signal transduction pathways
5 Repression of CD28 gene transcriptionS203
whole-cell lysates from the same cells were unimpaired
[57]. An understanding of the process of TCR/CD3
complex assembly provided the first clues as to the most
likely mechanism for this unexpected observation.
TNF impairs assembly and stability of the
TCR/CD3 complex at the cell surface
Current concepts of TCR/CD3 complex assembly have
been based largely on detailed molecular analyses in T-
cell hybridomas using metabolic labelling and pulse-chase
experiments. They describe a process where, for full func-
tion, the polymorphic TCRαβ chains associate with the
invariant chains (CD3 γ, δ, and ε and TCRζ) consisting of
noncovalently linked γε and  δε heterodimers and disul-
phide-linked  ζ–ζ homodimers, which transmit signals
inside the cell (Fig. 5). Association of TCRζ dimers with
newly synthesized hexameric complexes (αβγεδε) results
in the transport and subsequent expression of the com-
plete TCR/CD3 complex (αβγεδεζ2) at the cell surface.
Studies in T-cell hybridomas have revealed that TCRζ is
synthesized at ~10% of the rate of other components
[58], and therefore the amount of TCRζ available in a
given T cell is thought to regulate TCR/CD3 expression at
the cell surface.
Our results predicted that expression of TCRζ may be one
target of chronic TNF stimulation. Indeed, following closely
the kinetics of IL-2 downregulation, western blotting analy-
sis of whole-cell lysates revealed that chronic stimulation
with TNF suppressed the expression of TCRζ in a dose-
and time-dependent fashion, while concentrations of the
protein tyrosine kinases ZAP-70, p56Lck, and p59Fyn
were not altered [57]. Furthermore, immunoprecipitation
of CD3ε-containing complexes revealed normal concen-
trations of CD3ε, γ and δ, indicating that TNF had selec-
tive effects on TCRζ expression. Given that TCRζ might
be rate limiting for TCR/CD3 assembly, the data were
consistent with a model in which TNF appeared to disrupt
the assembly of TCR/CD3 complexes through its effects
on TCRζ expression. Profound reduction in concentra-
tions of cell-surface biotinylated TCRζ in TNF-treated T
cells strongly supported this notion [57].
A second unexpected experimental observation provided
further evidence that persistent TNF signalling in T cells
could perturb TCR/CD3 expression at the cell surface.
Immunoblotting analysis of unstimulated and TNF-stimu-
lated T cells revealed that the expression of the novel
transmembrane adaptor protein TRIM (T-cell-receptor-
interacting molecule) was markedly downregulated by
TNF treatment [59; Isomäki and Cope, unpublished data].
Closer examination revealed that TRIM expression was
reduced by TNF before changes in TCRζ expression
could be detected, and that reconstitution of both TRIM
and TCRζ expression was required to fully restore TCR
responsiveness in TNF-treated cells. The implications of
these findings have only recently become apparent,
through studies of TRIM expression in human peripheral
blood and Jurkat T cells. In collaborative studies with Dr
Burkhart Schraven, it was found that the half-life of
TCR/CD3 complexes in stable Jurkat clones overexpress-
ing TRIM is increased [60]. This in turn leads to increased
cell-surface expression of TCR and enhanced signalling
responses as determined by intracellular calcium mobilisa-
tion. We can conclude from these experiments that sus-
tained TNF signals in T cells impair TCR/CD3 assembly
not only through its effects on TCRζ expression, but also
by reducing the half-life of assembled complexes at the
cell surface by downregulating the expression of TRIM
(see Fig. 5). The kinetics of these changes, as well as the
precise interactions between TCRζ and TRIM, are now
being studied. Nevertheless, the findings provided a mole-
cular basis for the profound hyporesponsiveness of T cells
after TNF stimulation and predicted that downstream TCR
signalling pathways might be significantly attenuated as a
consequence of these structural constraints.
TNF attenuates membrane-proximal TCR
signalling pathways
One of the earliest events detected after TCR ligation is
the phosphorylation of tandemly arranged tyrosine
residues within immunoreceptor tyrosine-based activation
motifs (ITAMs) of TCRζ chain and CD3γ, δ, and ε chains
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Figure 4
The immunomodulatory effects of TNF during the evolution of the
immune response. After TCR ligation, TNF is costimulatory and required
for antigen priming. As the immune response proceeds over time, TNF
is required to suppress subsequent clonal expansion (TNF+/+; unbroken
line). In TNF-deficient animals (TNF–/–; dotted line), immune responses
are delayed, but, once established, they fail to resolve, leading to
persistent antigen reactivity. TNF, tumour necrosis factor-α.S204
by Src family kinases, notably Lck and Fyn [61]. In con-
trast to CD3 chains, which contain just one ITAM, TCRζ
carries three, providing the TCR/CD3 complex with a
signal sensor and amplification module [62,63]. In addi-
tion, TCRζ plays a role in proofreading extracellular
signals, since differences in the quality, intensity, and dura-
tion of the antigenic stimulus are translated into specific
patterns of TCRζ phosphorylation [64]. Once phosphory-
lated, TCRζ ITAMs function as docking sites for protein
tyrosine kinases of the Syk family, such as ZAP-70 [65].
The phosphorylation of several adaptor proteins by ZAP-
70 and Src kinases then serves as a link between mem-
brane-proximal phosphorylation events and the activation
of downstream signalling pathways leading to IL-2 produc-
tion, T-cell proliferation, and effector responses [61].
Given that TCRζ functions as a signal-amplification
module as well as a key component of TCR/CD3 complex
assembly, we reasoned that reduced expression of TCRζ
homodimers by TNF might impair membrane-proximal tyro-
sine phosphorylation events. A comprehensive analysis of
signalling pathways in control and TNF-treated T cells has
shown that concentrations of phospho-TCRζ are reduced
in TNF-treated T cells after TCR ligation [57]. Furthermore,
in spite of normal Lck kinase activity, the recruitment of
ZAP-70 to phospho-TCRζ through its SH2 domains and
its subsequent phosphorylation were also impaired. The
transmembrane adaptor protein linker for activation of T
cells (LAT) is an in vivo substrate for ZAP-70 kinase, and
plays a key role in linking membrane-proximal events with
both calcium and Ras/MAPK (mitogen-activated protein
kinase) pathways [66,67]. LAT phosphorylation was sub-
stantially reduced in TNF-treated cells, and, as predicted,
intracellular calcium mobilisation was also dramatically
attenuated [57]. The precise mechanisms for the down-
regulation of TCRζ expression by TNF are not clear.
However, TCRζ mRNA is reduced in T cells treated with
higher concentrations of TNF (2.5 ng/ml). Furthermore,
TNF may also reduce TCRζ concentrations indirectly
through the generation of reactive oxygen species, since
culture of TNF-treated T cells with the glutathione precur-
sor, N-acetylcysteine, reverses some but not all of the sig-
nalling defects we had documented in TNF-treated T cells,
possibly by restoring TCRζ expression [57]. Regardless of
the mechanisms, the data were consistent with a model in
which proximal signalling was impaired as a direct result of
the effects of TNF on TCRζ expression and phosphoryla-
tion and suggested a novel mechanism whereby the
inflammatory process might suppress T-cell reactivity in
RA synovial joints.
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Figure 5
Assembly and degradation of the TCR/CD3 complex. TCRζ and TRIM are required for assembly and stability of the TCR/CD3 complex at the cell
surface (see text for further details). ER, endoplasmic reticulum; TCR, T-cell receptor; TRIM, T-cell-receptor-interacting molecule.S205
Selective uncoupling of downstream
signalling by TNF
Since the transmembrane adaptor protein LAT functions
as a pivotal bifurcation point for downstream Ras/ERK
(extracellular signal-regulated kinase) and calcium sig-
nalling pathways [67], the reductions in concentrations of
phosphorylated LAT would predict that these downstream
pathways should be attenuated in TNF-treated T cells.
Several lines of preliminary evidence suggest that this pre-
diction may be too simplistic. We have been struck by the
extent to which TCR-induced calcium responses are
attenuated in TNF-treated T cells [49,57]. However, very
recent experiments have documented additional defects in
calcium signalling that arise through mechanisms indepen-
dent of the effects of TNF on membrane-proximal phos-
phorylation events and TCR/CD3 expression. For
example, while TNF depletes to only a modest extent the
thapsigargin-depletable intracellular calcium pool, TNF
attenuates to a much greater extent the influx of calcium
through store-operated ICRAC (calcium-release-activated
calcium current) channels ([68], and Fig. 6). The activation
of ICRAC calcium channels and influx of extracellular
calcium contributes significantly to the amplitude, dura-
tion, and kinetics of the total calcium signal, which in turn
is known to profoundly influence gene expression in T
cells [69]. We believe that this may provide an additional
mechanism through which TNF attenuates gene transcrip-
tion through calcium/NFAT-dependent pathways, and may
go some way to explain the profound proliferative and
cytokine hyporesponsiveness following TCR ligation that
we have observed after chronic TNF exposure.
We next undertook a systematic analysis of the Ras/ERK
pathway in control and TNF-treated T cells, expecting to
document similar degrees of attenuation. The results were
unexpected. While concentrations of TCR-induced GTP-
Ras are only modestly reduced in TNF-treated T cells,
phosphorylation of Raf-1, activation of ERK1/2, induction
of c-Fos, and TCR-induced expression of CD69 are unam-
biguously preserved. These results would predict that AP
(activator protein)-1 transactivation is likely to be spared in
TNF-treated T cells. If this is found to be the case, the data
define a novel biochemical basis for acquired suppression
of T-cell activation based upon selective attenuation of the
calcium but not of the Ras/ERK pathways (Fig. 7). At the
biochemical level, this result is of particular interest given
the observations that anergic T cells have reciprocal
defects, namely, reductions in TCR-induced Ras/ERK acti-
vation, while calcium responses are spared [70,71].
Aberrant signal transduction pathways in
synovial T cells in rheumatoid arthritis
The effects of chronic TNF described above have pro-
vided an experimental framework for exploring the role of
inflammatory cytokines in regulating the phenotype of syn-
ovial T cells from inflamed joints of patients with RA. Many
of the features of T cells chronically exposed to TNF
resemble RA synovial T cells (see Tables 1 and 2). Most
notable among these are the nondeletional, reversible T-
cell hyporesponsiveness [31–33], the upregulation of cell-
surface antigens [20], and the repression of CD28 gene
expression [72]. These similarities suggest that TNF may
play a role in driving this phenotype, and raise the intrigu-
ing possibility that there may also be similarities in terms of
the aberrations of intracellular signalling pathways that
might account for this phenotype.
The pioneering studies of Verweij and colleagues in this
field have perhaps most comprehensively and systemati-
cally documented proximal TCR signalling in synovial-fluid
T cells [73]. The most relevant to this discussion is the
downregulation of TCRζ chain expression in synovial-fluid
T cells in comparison with peripheral blood, as determined
by flow cytometry, immunoblotting, or immunohistochem-
istry [73,74]. Expression and phosphorylation of p36LAT
and its recruitment to the plasma membrane is also
reduced in synovial-fluid T cells [75], and both this phe-
nomenon and the loss of TCRζ expression can be
reversed at least partially by restoring concentrations of
glutathione by culturing T cells ex vivo with N-acetylcys-
teine [73,75]. This is an important finding, since it indi-
cates that TCR signalling pathways are sensitive to
reactive oxygen species and redox potential. More recent
data indicate that the generation of such oxygen species
is regulated by Ras, which is itself expressed in a constitu-
tively active GTP bound form in synovial T cells, and that
increased concentrations of these oxygen species may
influence the tertiary structure and conformation of LAT at
the plasma membrane [76].
The similarities between synovial T cells and T cells gener-
ated in vitro after repeated TNF stimulation extend further
to calcium responses, including influx through ICRAC chan-
nels, which are also attenuated in peripheral blood and
joint T cells from patients [77,78], as well as in Jurkat T
cells treated with TNF [79]. Using a completely different
approach, Isaacs and colleagues have compared the char-
acteristics of anergic CD4+ T cells and RA synovial T cells
at the mRNA level by differential display RT-PCR [80].
One striking transcriptional event common to both sets of
T cells was the downregulation of calmodulin, a gene
whose product plays an important role in coupling calcium
responses to downstream pathways. Indeed, transcription
of calmodulin in RA synovial T cells was less than 1% that
in synovial samples from patients with reactive arthritis,
who served as the controls in these studies. Expression in
synovial T cells was lower than that observed in paired
peripheral blood T cells. Interestingly, calmodulin tran-
scripts increased 5- to 10-fold after TNF blockade in vivo
in all six patients studied. Thus, the findings of impaired
calcium responses on the one hand, and constitutively
active Ras on the other, provide compelling evidence of
Available online http://arthritis-research.com/content/4/S3/S197S206
selective uncoupling of TCR signalling in chronically active
T cells in vivo, similar to that observed in TNF-treated T
cells (see Fig. 7). Moreover, direct comparisons of periph-
eral blood and joint T cells have established hierarchical
attenuation of signalling pathways from peripheral blood to
the joint, with the most profound defects being observed
in the joint [73–75], suggesting that these signalling
anomalies are not inherited but are likely to be acquired
through chronic exposure to the environment in inflamed
joints over prolonged periods of time.
Are there any clues suggesting selective activation of
downstream signalling pathways leading to specific tran-
scriptional events at the nuclear level? Data up to now are
scarce, but there are isolated reports of constitutive NF-
κB activation in RA synovial T cells [81]. The finding of
constitutive activation of NF-κB in synovial T cells is of
particular interest given the recent studies demonstrating
the beneficial therapeutic effects of a T-cell selective NF-
κB inhibitory compound (SP100030) in collagen-induced
arthritis [82]. The same group have documented attenua-
tion of adjuvant arthritis in rats using dominant negative
IKKβ (inhibitor of NF-κB kinase β) delivered by adenoviral
vector [83], although when this approach is used, inhibi-
tion of NF-κB would not be confined to T cells. In addition,
a recent analysis of constitutive MAPK activation in syn-
ovial tissue suggests that there may be preferential activa-
tion of ERK in lymphoid aggregates in perivascular tissue
[84]. It is perhaps premature to draw any firm conclusions
about which transcription factors are active in synovial T
cells, other than to state that there is evidence for consti-
tutive activation of pathways in vivo that exert a potential
for promoting the inflammatory process, and perhaps cell
survival.
Implications for the pathogenesis of chronic
inflammatory disease
The effects of TNF on downstream TCR signalling path-
ways outlined above, together with the studies of calcium
signalling in synovial T cells from patients with RA, predict
that transactivation of NFAT should be dramatically
reduced in the synovial joint. If this indeed is the case,
then it provides a molecular framework for exploring
further how the inflammatory process might influence
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Figure 6
The calcium/calcineurin/NFAT signalling pathway in T cells. After TCR ligation and PLCγ1 activation, newly synthesized IP3 binds to tetrameric IP3
receptor complexes inducing the release of intracellular calcium stores from the sarco-endoplasmic reticulum. Store depletion leads directly to the
opening of ICRAC or store-operated channels (SOC) in the plasma membrane through mechanisms that are unclear. This leads ultimately to
activation of the serine phosphatase calcineurin, dephosphorylation of NFAT, and translocation of this transcription factor to the nucleus. For many
genes, NFAT binds cooperatively to AP-1 complexes for optimal gene transcription. AP, activator protein; CsA, cyclosporin A; iCa2+, intracellular
calcium; ICRAC, calcium-release-activated calcium current; IP, inositol phosphate; P, phosphate group; PLCγ, phospholipase Cγ; TCR, T-cell
receptor.S207
immunity and inflammation in vivo. For example, NFAT is
required for the transcription of many genes involved in the
initiation of the immune response, cell growth and differen-
tiation, the induction of immunoregulatory cytokines, host
defence, and resolution of the immune response through
activation-induced cell death [85]. Accordingly, defects in
this pathway would lead not only to depressed immunity
and the failure to generate productive Th effector
responses, but also to the failure of tolerance by impaired
TCR-induced expression of FasL (Fas ligand), attenuation
of activation-induced cell death, and the failure to mount
significant immunoregulatory responses.
Our own studies of the effects of chronic TNF signalling
emphasise the potential for cytokine-dependent, antigen-
independent effector mechanisms, driven perhaps through
chronic stimulation of the NF-κB pathway. Sustained NF-
κB activation would promote trafficking to sites of inflam-
mation, as well as enhance the survival of cells in the
inflamed joint, thereby promoting effector responses
dependent on cell-to-cell interactions [86,87]. Preliminary
phenotyping and genotyping analyses in our laboratory
suggest that a number of potential candidates may be
upregulated on the cell surface of TNF-treated T cells as a
direct consequence of chronic NF-κB activation. These
include RANK (receptor activator of nuclear factor κB)
ligand, whose upregulation enhances osteoclastogenesis
and bone resorption; β integrins, which promote T-cell
trafficking to inflamed joints; and CD69, a surface antigen
that has been shown to promote signalling between
macrophages and T cells and inflammatory cytokine pro-
duction [87]. This switch from ‘antigen mode’ to ‘inflam-
mation mode’ and the generation of antigen-independent
effector responses in T cells (see Fig. 2) suggests that
conventional therapeutic approaches for modulating T-cell
reactivity may need to be revised.
Future prospects for therapy
It has long been recognised that cellular immunity and, in
particular, T-cell activation are restored after treatment
with remission-inducing therapy, regardless of the
disease-modifying agent. We now know that anti-TNF
treatment is no exception [44]. The question of whether
inflammatory disease remits as a consequence of the
recovery of immune competence or in spite of it has never
been addressed in depth. On the basis of the available
data, we can only conclude that recovery of T-cell reactiv-
ity is compatible with attenuation of the disease process
and does not seem to exacerbate the inflammatory
process. The possibility that normalisation of function of a
subset of specific T cells with anti-inflammatory activity
occurs is consistent with this conclusion.
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Figure 7
TCR signal transduction pathways. Engagement and stabilisation of TCR/CD3 complexes leads to a membrane-proximal cascade of tyrosine
phosphorylation events that ultimately lead to the activation of kinases and transcription factors directly involved in gene transcription. Ligation of
TCR and costimulatory receptors leads to activation of multiple pathways, including ERK, JNK, NF-κB, and NFAT (left panel). Impaired assembly
and stability of the TCR/CD3 complex would be expected to attenuate all downstream pathways (middle panel). However, chronic TNF stimulation
leads to selective uncoupling of TCR signalling, such that TCR-induced calcium/NFAT responses are impaired, while Ras/ERK activation is spared
(right panel). The effects of proinflammatory cytokines on the activation of these specific pathways are not included here. ERK, extracellular 
signal-regulated kinase; Jnk, c-Jun N-terminal kinase; NF, nuclear factor; NFAT, nuclear factor of activated T cells; TCR, T-cell receptor.S208
Results from several laboratories, including our own,
suggest that therapeutic strategies aimed at restoring
T-cell homeostasis should be given serious consideration,
and should in addition take into account the effects of the
inflammatory process on thymic function [50,80,88,89].
This therapeutic approach is in line with the thesis propos-
ing that susceptibility to autoimmunity arises not through
clonal expansion of autoaggressive effector T cells as a
primary event, but more through the failure of the adaptive
immune system to regulate an inflammatory response [90].
How could recovery of T-cell regulatory activity be
achieved in man? A major challenge in the short term will
be to define more precisely a phenotype for regulatory T-
cell subsets so that their frequency can be studied in
peripheral blood and at sites of inflammation. It would be
of particular interest to establish whether their TCR sig-
nalling responses and regulatory function correlate
inversely with disease activity. Such studies might include
analyses of the new generation of ‘suppressor’ T cells
such as IL-10-producing, Tr1-like CD4+ cells,
CD4+CD25+ regulatory T cells, or IL-16-producing CD8+
T cells [91–94]. If, in the longer term, antigenic specificity
can be established, T-cell responsiveness could be
restored towards ‘normal’ (but not beyond) by combining
peptide therapy with anti-TNF. Precise knowledge of the
specific TCR signalling defects could facilitate the moni-
toring of such therapy, so that any potential for rebound
hyper-reactivity of bystander T cells and its deleterious
consequences, including systemic autoimmune disease,
could be substantially reduced [95,96]. Anti-TNF in com-
bination with nondepleting anti-CD4 or anti-CD3 mAb
might have similar beneficial therapeutic effects.
There exists an alternative to the hypothesis that the
acquisition of T-cell hyporesponsiveness promotes the
inflammatory process. For example, defective T-cell reac-
tivity at sites of inflammation may turn out to be an essen-
tial adaptive response for suppressing autoreactivity, as
suggested by studies in mice (50,88). In this event, it
would be important to understand how the inflammatory
process uncouples signalling pathways, since this might
facilitate the development of novel immunosuppressive
agents. Rather than target pathways that are already sup-
pressed, such as the calcium/calcineurin pathway, these
strategies might attenuate those that are dominant and
that drive the inflammatory process. According to this
model, the Ras/ERK and NF-κB signalling pathways
would be good candidates.
Concluding remarks
The molecular events that shape the early phase of Th cell
differentiation in regional lymph nodes are quite likely to be
distinct from those imposed by the environment of an
inflamed joint. It follows from this that the design of strate-
gies for manipulating T-cell effector responses should be
governed by the chronicity of the immune response. Until
now, therapies that target T cells have been based largely
upon the potency of agents in acute immunoinflammatory
responses in the laboratory. With a growing knowledge
base of the characteristics and phenotype of chronically
activated T cells, we can look forward to a new generation
of therapeutics targeting selective intracellular pathways
involved directly in promoting the chronic inflammatory
process. Whether such strategies will necessitate targeted
immunoablation or restoration of T-cell homeostasis remains
to be seen. However, when considering the available
options, it should be borne in mind that protection against
foreign pathogens is the primary function of the immune
system and that this immunity is provided to the host at the
expense of a huge propensity for cross-reactivity to self
tissue antigens. My own bias, which is derived in part from
the working model illustrated in Fig. 2, would be to focus on
methods of reconstituting the immune system of patients
with the regulatory networks that keep this cross-reactivity
in check and the vast majority of individuals in good health.
Glossary of terms
c-Maf = a transcription factor specific for Th2 cells; ERM = a
transcription factor specific for Th1 cells; ICRAC = calcium-
release-activated calcium current; ITAM = immunoreceptor
tyrosine-based activation motifs; GATA-3 = a transcription
factor specific for Th2 cells; T-bet = a transcription factor
specific for Th1 cells.
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